TriangleNCT01207388 · CITED IN SOURCE DOCUMENTS
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2020-02-10
The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle
Hematological Relapse-free Survival (RFS)
Overall Survival
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant
Time to Hematological Relapse
Duration of Complete MRD Response
Change in MRD Level From Baseline to End of Cycle 1 in Non-MRD Responders
Number of Participants With Adverse Events
Change From Baseline in EORTC-QLQ-C30 Scales
Change From Baseline in EuroQoL 5-Dimension (EQ-5D) Scales
Resource Utilization: Number of Participants Reporting Use of Transfusion of Blood Products
Resource Utilization: Duration of Hospitalization
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Patients with B-precursor ALL in complete hematological remission after at least 3 intense chemotherapy blocks * Presence of minimal residual disease at a level of ≥ 10\^-3 * Availability of bone marrow specimen from primary diagnosis for clone-specific MRD assessment * Negative human immunodeficiency virus (HIV) test, negative hepatitis B (HbsAg) test and hepatitis C virus (anti-HCV) test * Negative pregnancy test in women of childbearing potential * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: * Presence of circulating blasts or current extra-medullary involvement by ALL * History of relevant central nervous system (CNS) pathology or current CNS pathology * Prior allogeneic hematopoietic stem cell transplant (HSCT) * Eligibility for treatment with tyrosine-kinase inhibitors (TKI) * Systemic cancer chemotherapy within 2 weeks prior to study treatment * Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to study treatment * Previous treatment with blinatumomab
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
- intervention Names
- Drug: Blinatumomab
- label
- Blinatumomab
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Blinatumomab
- description
- Continuous intravenous infusion
- name
- Blinatumomab
- other Names
- AMG 103
- MT103
- BLINCYTO™
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 116
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory. Complete MRD response is defined as no polymerase chain reaction (PCR) amplification of individual rearrangements of immunoglobulin (Ig)- or T-cell receptor (TCR)-genes detected after completion of the first cycle.
- measure
- Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle
- time Frame
- During the first cycle (6 weeks)
- secondary Outcomes
- description
- Hematological RFS was measured from first dose of blinatumomab until the first assessment of documented relapse (either hematological or extramedullary), secondary leukemia, or death due to any cause. Participants without a documented relapse, or death due to any cause were censored at the time of their last hematological assessment. Participants who received chemotherapy for relapsed or persistent MRD or for any other reason after treatment with blinatumomab, or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse, or death occurred were censored at the start of chemotherapy or HSCT, respectively. Hematological relapse was defined as unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological, microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia (whichever occurred first). The 18-month Kaplan-Meier estimate of hematological RFS is reported.
- measure
- Hematological Relapse-free Survival (RFS)
- time Frame
- 18 months, up to the data cut-off date of 05 August 2015
- description
- Overall survival was measured from the first treatment with blinatumomab until death due to any cause. Participants who did not die were censored at their last contact date.
- measure
- Overall Survival
- time Frame
- Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
- description
- The mortality rate within 100 days after allogeneic HSCT was defined as the Kaplan-Meier estimate of the percentage of participants dying within 100 days after the day of the first allogeneic HSCT.
- measure
- 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant
- time Frame
- 100 days after HSCT, as of the data cut-off date of 05 August 2015
- description
- Time to hematological relapse was measured from the start of treatment with blinatumomab until hematological or extramedullary relapse. Participants who died or received HSCT or post-blinatumomab chemotherapy after treatment with blinatumomab were censored at their last hematological assessment prior to death or HSCT or post-blinatumomab chemotherapy (whichever occurred first).
- measure
- Time to Hematological Relapse
- time Frame
- Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
- description
- The duration of MRD response was analyzed as the time from onset of MRD negativity until MRD or hematological relapse or date of last confirmation of negative MRD status. Participants who received chemotherapy or HSCT after treatment with blinatumomab, before hematological or extramedullary relapse were censored at the start of chemotherapy or HSCT, respectively. MRD relapse is defined as the reappearance of individual rearrangements of Ig- or TCR-genes ≥ lower limit of quantification (LLOQ) for at least 1 individual marker measured by an assay with a sensitivity of minimum 10\^-4. Hematological relapse is defined as the unequivocal detection of \> 5% leukemia cells in bone marrow as measured by cytological or microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia.
- measure
- Duration of Complete MRD Response
- time Frame
- Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
- description
- MRD level was measured by polymerase chain reaction (PCR) performed on bone marrow and assessed by the central laboratory. An MRD level of 10\^-n corresponds to residual leukemia cells at a frequency of 1 per 10ⁿ bone marrow cells.
- measure
- Change in MRD Level From Baseline to End of Cycle 1 in Non-MRD Responders
- time Frame
- Baseline and end of cycle 1 (6 weeks)
- description
- Adverse events (AEs) were evaluated for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. An AE was considered "serious" if it resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions, was a congenital anomaly or birth defect or was a medically important condition.
- measure
- Number of Participants With Adverse Events
- time Frame
- From the first dose of blinatumomab until 30 days after last dose; the median treatment duration was 55 days.
- description
- The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. The maximum changes from baseline to cycles 1 through 4 and the change from baseline to the end of the core study are reported.
- measure
- Change From Baseline in EORTC-QLQ-C30 Scales
- time Frame
- Baseline and the end of each treatment cycle (day 29 of each cycle) and 30 days after end of the last infusion (end of the core study, a maximum of 26 weeks).
- description
- The EQ-5D is a self-administered questionnaire which captures 3 basic types of information: a descriptive profile (health state index) and the overall health rating using a visual analog scale. The health state index measures mobility, self-care, usual activities, pain/discomfort and anxiety/depression on scales from no problems (score = 1), some problems (score = 2), to extreme problems (score = 3). For each dimension the mean change from baseline was calculated at the end of each treatment cycle and at the end of the core study. The maximum observed change from baseline during cycles 1 to 4 and the change from baseline at the end of the core study are reported for each dimension.
- measure
- Change From Baseline in EuroQoL 5-Dimension (EQ-5D) Scales
- time Frame
- Baseline and the end of each treatment cycle (day 29 of each cycle) and 30 days after end of the last infusion (end of the core study, a maximum of 26 weeks).
- measure
- Resource Utilization: Number of Participants Reporting Use of Transfusion of Blood Products
- time Frame
- From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months
- measure
- Resource Utilization: Duration of Hospitalization
- time Frame
- From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months.
Full study description
- brief Summary
- The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
- detailed Description
- The detection of minimal residual disease (MRD) after induction therapy and/or consolidation therapy is an independent prognostic factor for poor outcome of adult ALL. No standard treatments are available for patients with MRD-positive B-precursor ALL. Blinatumomab (MT103) is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T-cell activation and a cytotoxic T-cell response against cluster of differentiation (CD)19 expressing cells. The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease. Participants will receive up to four 4-week cycles of intravenous blinatumomab treatment followed by an infusion-free period of 14 days. A safety follow-up will be performed 30 days after the end of the last infusion and efficacy follow-ups will occur until 24 months after treatment start. Participants will be followed for up to 5 years after the start of treatment for survival.
Source references
- references
- citation
- Chevallier P. Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT? Lancet Haematol. 2024 Jan;11(1):e12-e13. doi: 10.1016/S2352-3026(23)00365-4. No abstract available.
- pmid
- 38135369
- type
- DERIVED
- citation
- Gokbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, Faul C, Bruggemann M, Taylor K, Mergen N, Reichle A, Horst HA, Havelange V, Topp MS, Bargou RC. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020 Nov;61(11):2665-2673. doi: 10.1080/10428194.2020.1780583. Epub 2020 Jul 3.
- pmid
- 32619115
- type
- DERIVED
- citation
- Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, Sridhara R, Deisseroth A, Philip R, Farrell AT, Pazdur R. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease. Clin Cancer Res. 2019 Jan 15;25(2):473-477. doi: 10.1158/1078-0432.CCR-18-2337. Epub 2018 Sep 25.
- pmid
- 30254079
- type
- DERIVED
- citation
- Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Bruggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.
- pmid
- 29358182
- type
- DERIVED
- citation
- Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4.
- pmid
- 27209293
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-ce288d87b21320b1f1c0
- requested nct id
- NCT01207388
- primary nct id
- NCT01207388
- source kind
- fda_spl_label
- source record id
- 4a2c4b49-a991-4ac7-80b3-4b2f8f62de30
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- payload sha256
- d0eef0fdeb794eb53d83686c5b33334247d98fcdf650f81923cded3d53ea486c
- payload
- application numbers
- BLA125557
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-ce288d87b21320b1f1c0
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01207388
- occurrences
- context exact
- TUDIES 14.1 MRD-positive B-cell Precursor ALL BLAST Study The efficacy of BLINCYTO was evaluated in an open-label, multicenter, single-arm study (BLAST Study) [NCT01207388] that included patients who were ≥ 18 years of age, had received at least 3 chemotherapy blocks of standard ALL therapy, were in hematologic complete remission
- end
- 184
- exact text
- NCT01207388
- start
- 173
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00200.json
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source json pointer
- /results/96/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 4a2c4b49-a991-4ac7-80b3-4b2f8f62de30
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- ee9813b8f71c61d363e23bfc59b27d2253842edd8917d0654ef29ed2dd764485
- spl effective time
- 20260414
- spl set id
- 38b482a8-960b-4591-9857-5031ecb830aa
Preserved source evidence · Not medical advice